MedicineAll countries · Checked
Tirzepatide (Zepbound, Mounjaro) for Weight Loss: Doses, Cost and Is There a Pill?
Tirzepatide is a once-weekly injection, and there is no tirzepatide pill. As of November 2026, the weight-loss brand is Zepbound in the US and Canada and Mounjaro in the UK and the EU.
Tirzepatide at a glance
One medicine, two brand names: Zepbound and Mounjaro are the same injection ingredient.
Medicine and makerTirzepatide, Eli Lilly
How you take itInjection, once a week
Dose range2.5 mg start, 15 mg maximum
The Lilly weight-loss pillFoundayo, a different drug
Doses are from the US Zepbound label.
Once you know the dose, the price follows.
See the price of each Zepbound dose in the USIn the UK? See the Mounjaro price in the UK.
Weight lossPill?Zepbound vs MounjaroZepboundCanadaDoseResultsSide effectsCostGenericFAQ
Tirzepatide for weight loss
Tirzepatide switches on the receptors for two gut hormones, GIP and GLP-1. It is approved for weight loss alongside a reduced-calorie diet and more exercise.
The US label covers adults with obesity, and adults with overweight who have at least one weight-related condition. In the UK the cutoffs are a BMI of 30 or more, or 27 to 30 with a weight-related problem.
You can check your own number with the BMI calculator.
The FDA approved Zepbound for weight management on November 8, 2023. The UK regulator, the MHRA, authorized Mounjaro for weight management the same day.
The Zepbound label has a second use: treating moderate to severe obstructive sleep apnea in adults with obesity.
Tirzepatide pill: is there one?
No. Every tirzepatide product on the US label is an injection: single-dose pens, single-dose vials, and four-dose multi-dose vials and KwikPens.
Lilly's weight-loss pill is a different drug. It is called Foundayo, its ingredient is orforglipron, and the FDA approved it on April 1, 2026.
Foundayo is a once-daily tablet taken with or without food. It starts at 0.8 mg and goes up no faster than every 30 days, to a maximum of 17.2 mg.
The two get mixed up because both come from Lilly. Doses and prices for the pill are in Foundayo (orforglipron).
Zepbound vs Mounjaro
The ingredient and the doses are the same. What differs is the name and which uses are approved in your country.
Brand used for weight loss
United StatesZepbound
CanadaZepbound KwikPen
United KingdomMounjaro
European UnionMounjaro
The Mounjaro side, including its diabetes use, is in Mounjaro (tirzepatide).
What is Zepbound?
Zepbound is the tirzepatide injection approved for weight loss and sleep apnea. You inject it under the skin once a week.
The label does not recommend using it together with other tirzepatide products or with any other GLP-1 medicine.
US prices change by dose, and Lilly runs a savings program. The current LillyDirect prices and card rules are in Zepbound savings card and LillyDirect prices.
Zepbound Canada
Health Canada authorized Zepbound KwikPen for chronic weight management on May 13, 2025, as a once-weekly injection.
Eli Lilly Canada announced on July 9, 2025 that the pen was available.
It is for adults with a BMI of 30 or more, or a BMI of 27 to under 30 with at least one weight-related condition such as high blood pressure or type 2 diabetes.
Canadian prices by dose are in Mounjaro price in Canada.
Tirzepatide dose
Everyone starts at 2.5 mg once a week for 4 weeks. After at least 4 weeks on a dose, it can go up by 2.5 mg.
Tirzepatide doses in brief
Starting dose2.5 mg for 4 weeks
Weight-loss maintenance doses5, 10 or 15 mg
Sleep apnea maintenance doses10 or 15 mg
Maximum dose15 mg once a week
Your maintenance dose depends on how well the medicine works and how well you tolerate it, so not everyone goes to 15 mg.
The week-by-week chart is in Zepbound dosing schedule. Missed doses and the half-life of about 5 days are in tirzepatide half-life.
Tirzepatide weight loss results
The largest trial followed 2,539 adults with obesity or overweight, without diabetes, for 72 weeks.
5 mg−15.0%10 mg−19.5%15 mg−20.9%
People on placebo lost 3.1% on average.
In a second 72-week trial of 938 adults with type 2 diabetes, the average loss was 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo.
These are trial averages, not a promise for any one person. Everyone in the trials also ate fewer calories and exercised more.
Tirzepatide side effects
The most common side effects are in the stomach and gut: nausea, diarrhea, vomiting, constipation and stomach pain.
In the weight-loss trials, nausea affected 8% on placebo and 25%, 29% and 28% on 5, 10 and 15 mg.
Diarrhea affected 8%, 19%, 21% and 23%. Vomiting affected 2%, 8%, 11% and 13%.
The US label has a boxed warning on thyroid C-cell tumors, which appeared in rats. Whether it applies to people has not been determined.
You cannot use tirzepatide if you or your family have had medullary thyroid cancer or MEN 2. Your prescriber checks this before the first dose.
Tirzepatide cost
Prices change a lot by country, dose and program, so the numbers live on the country pages instead of here.
US prices per dose are in Zepbound cost per dose. UK prices are in Mounjaro price UK.
To work out your own monthly cost, use the GLP-1 cost calculator.
Is there generic tirzepatide?
Tirzepatide is the ingredient name. It does not mean a cheaper copy of the brands.
Whether a generic exists is covered in generic tirzepatide.
Tirzepatide FAQ
Is there a tirzepatide pill?
No. Tirzepatide comes only as an injection. Lilly's pill is Foundayo, which contains orforglipron.
Are Zepbound and Mounjaro the same medicine?
Yes. Both are tirzepatide, with the same doses from 2.5 mg to 15 mg.
How often do you take tirzepatide?
Once a week, on the same day each week.
Can you get Zepbound in Canada?
Yes. Health Canada authorized it on May 13, 2025, and it was announced as available on July 9, 2025.
Can I use tirzepatide with another GLP-1 medicine?
No. The label does not recommend using it with another GLP-1 medicine.
Keep reading
Zepbound savings card and LillyDirect prices
Tirzepatide FDA approval dates
This page follows the US Zepbound label and the FDA, MHRA and Health Canada announcements, and is updated when they change. See how we check our pages.
Update log
: First published.
Sources
Zepbound US prescribing information (Eli Lilly), revised 11/2026.
FDA approves new medication for chronic weight management (US FDA, November 8, 2023).
MHRA authorises Mounjaro for weight management (UK government).
Zepbound KwikPen approved and available in Canada (Eli Lilly Canada).
Foundayo US prescribing information (US FDA).
GLP1 Note is an independent information site. Your own dose and medicine are chosen by your prescriber.